Search

Background: Previous studies suggested protective effects of bilirubin against cardiovascular disease, with a possible gender difference. However, the relationship between serum total bilirubin (TBIL) with diabetic macro- and microvascular complications remains unknown. We aimed to examine the association of macro- and microvascular complications with serum TBIL levels. Methods: Serum TBIL was measured in 648 patients with T2DM. Demographic and clinical data were obtained from the inpatient medical record system. Serum TBIL was measured with an automatic biochemistry analyzer according to routine protocols. Parameters of vascular complications, including ankle-brachial index, carotid intima-media thickness, estimated glomerular filtration rate and the urinary albumin to creatinine ratio, were measured and calculated. The association between TBIL and diabetic macro- and microvascular complications was analyzed. Results: In multivariable logistic regression, after adjustment for age, sex, body mass index and diabetic duration, higher serum TBIL levels were significantly associated with decreased odds of microalbuminuria (OR = 0.31, [95% CI] 0.16– 0.61, P = 0.003) and chronic kidney disease (OR = 0.19, [95% CI] 0.09– 0.41, P < 0.001). These associations were only found in male but not in female patients. However, no significant relationship was found between TBIL and peripheral arterial disease or carotid hypertrophy. Conclusion: Our findings suggest that physiological higher TBIL level might be a protective factor for diabetic microvascular complications. [ABSTRACT FROM AUTHOR]

Objective: Adipokines, such as adiponectin and chemerin, regulate fat metabolism and are critical for the development of atherosclerosis. Investigating the correlations of adiponectin and chemerin with atherosclerosis in older adults with type 2 diabetes mellitus (T2DM) will shed light on the search for new markers for early diagnosis of diabetic atherosclerosis. Methods: A total of 120 older T2DM patients and nine healthy controls were enrolled in this study. The clinical parameters, such as brachial‐ankle pulse wave velocity (ba‐PWV), adiponectin, and chemerin, were examined and recorded. T2DM subjects were divided into three groups according to ba‐PWV level (high, medium, or low). The data were processed and analyzed by identical methods. Results: Significantly higher chemerin and lower adiponectin levels were detected in the plasma of T2DM patients than in healthy controls. The plasma levels of chemerin and adiponectin were negatively correlated in T2DM patients. Moreover, chemerin and adiponectin were significantly correlated with body mass index, ankle‐brachial index, insulin, and ba‐PWV. Multiple linear regression analysis revealed that chemerin and adiponectin were independently affecting ba‐PWV. Conclusion: Adiponectin and chemerin are potential markers for diagnosis and monitoring of early stage of atherosclerosis in older adults with T2DM. Further clinical investigations are required to confirm these markers. [ABSTRACT FROM AUTHOR]

Type 2 diabetes [T2D] and thyroid dysfunction [TD] often co-occur, have overlapping pathologies, and their risk increases with age. Since 1995, universal salt iodization has been implemented in China to prevent disorders caused by iodine deficiency. However, after two decades of implementation of universal salt iodization, the prevalence of TD in elderly Chinese patients with T2D is not well described and may have been underestimated. We conducted a questionnaire-based survey across 24 endocrinology centers in China between December 2015 and July 2016. Demographic and clinical data from 1677 patients with T2D were obtained and analyzed to examine the prevalence of TD along with T2D in these patients. We assessed TD prevalence according to the four TD subtypes [subclinical hypothyroidism, clinical hypothyroidism, subclinical hyperthyroidism, and clinical hyperthyroidism], TD history, gender, and age. The diagnosis rates were calculated for TD and also for the TD subtype. The number of patients reaching treatment goals for T2D [hemoglobin A1c <7%] and TD [normal free thyroxine and thyroid-stimulating hormone [TSH]] and the incidences of complications and comorbidities were recorded. Among the enrolled patients with T2D [N = 1677], TD was diagnosed in 23.79% [399/1677] out of which 61% (245/399) were previously diagnosed and 38.59% (154/399) were newly diagnosed cases. Subclinical hypothyroidism, clinical hypothyroidism, subclinical hyperthyroidism, and clinical hyperthyroidism were reported in 4.89%, 9.3%, 1.13%, and 3.16% of the total population, respectively. Among patients previously diagnosed with TD, the incidence in women [166/795; 20.88%] was higher than in men [79/882; 8.96%]. The treatment goals for TD and T2D were attained in 39.6% [97/245] and 34.41% [577/1677] of the cases, respectively. Diabetic complications and comorbidities were reported in 99.7% of patients, with peripheral neuropathy being the most common [43.46%] followed by cataract [24.73%]. We had found that the incidences of dyslipidemia, elevated LDL levels, and osteoporosis were significantly higher in patients with TD than those without TD. TD is underdiagnosed in elderly Chinese patients with T2D. [ABSTRACT FROM AUTHOR]